Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells.

Patchett, Amanda L; Wilson, Richard; Charlesworth, Jac C; Corcoran, Lynn M; Papenfuss, Anthony T; Lyons, Bruce A; Woods, Gregory M; Tovar, Cesar

Patchett, Amanda L; Wilson, Richard; Charlesworth, Jac C; Corcoran, Lynn M; Papenfuss, Anthony T; Lyons, Bruce A; Woods, Gregory M; Tovar, Cesar.

Afiliación

Patchett AL; Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia.
Wilson R; Central Science Laboratory, University of Tasmania, Hobart, Tasmania 7001, Australia.
Charlesworth JC; Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia.
Corcoran LM; Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Papenfuss AT; Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia.
Lyons BA; Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
Woods GM; Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia.
Tovar C; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.

Oncotarget ; 9(22): 15895-15914, 2018 Mar 23.

Article en En | MEDLINE | ID: mdl-29662615

Palabras clave

Tasmanian devil; cancer; devil facial tumor disease; imiquimod; immunotherapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Australia